Clinical & experimental pharmacology最新文献

{"title":"Predicting the Severity of Disease Progression in COVID-19 at the Individual and Population Level: A Mathematical Model","authors":"N. Chirmule, R. Khare, P. Nair, B. Desai, V. Nerurkar, A. Gaur","doi":"10.35248/2161-1459.21.11.283","DOIUrl":"https://doi.org/10.35248/2161-1459.21.11.283","url":null,"abstract":"The impact of COVID-19 disease on health and economy has been global, and the magnitude of devastation is unparalleled in modern history. Any potential course of action to manage this complex disease requires the systematic and efficient analysis of data that can delineate the underlying pathogenesis. We have developed a mathematical model of disease progression to predict the clinical outcome, utilizing a set of causal factors known to contribute to COVID-19 pathology such as age, comorbidities, and certain viral and immunological parameters. Viral load and selected indicators of a dysfunctional immune response, such as cytokines IL-6 and IFNα which contribute to the cytokine storm and fever, parameters of inflammation D-Dimer and Ferritin, aberrations in lymphocyte number, lymphopenia, and neutralizing antibodies were included for the analysis. The model provides a framework to unravel the multi-factorial complexities of the immune response manifested in SARS-CoV-2 infected individuals. Further, this model can be valuable to predict clinical outcome at an individual level, and to develop strategies for allocating appropriate resources to manage severe cases at a population level.","PeriodicalId":90141,"journal":{"name":"Clinical & experimental pharmacology","volume":"89 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87384351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chlorpheniramine maleate nasal spray in COVID-19 patients: Case Series","authors":"Joselit Torres, Camille C. Go, Farah A. Chohan, G. L., M. Sanchez-Gonzalez, Gustavo Ferrer","doi":"10.21203/RS.3.RS-138252/V1","DOIUrl":"https://doi.org/10.21203/RS.3.RS-138252/V1","url":null,"abstract":"\u0000 The pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) posted a devastating global health crisis for almost a year already. Very little is known about this virus that scientists, physicians and the medical community struggled to find treatments of this novel virus. The vaccine that can potentially combat this virus is still an unknown reality hence, the repurposing of existing medical treatments such as chlorpheniramine maleate (CPM) could be a possible treatment and is being widely utilized. CPM is a safe and effective antihistamine with potent antiviral activity against various strains of influenza A/B, thus highlighting its great antiviral potential. We tested the virucidal potential of chlorpheniramine maleate (CPM) in a nasal spray composition currently in development as an anti-allergy medication. The coronavirus disease 2019 (COVID-19) has a droplet mode transmission with a notably high viral load in the upper respiratory tract, especially the nose. Several studies had already postulated that the nose is possibly the primary route of entry of SARS-CoV-2 owing to the high expression of Angiotensin 2 converting enzyme receptors. We hypothesize that utilizing (CPM) nasal spray as an adjunct treatment to COVID-19 positive patients and reduce their clinical course and hasten their time to negativization via RT-PCR via nasopharyngeal swab. We present a series of four symptomatic patients with mild-moderate risks. CPM nasal spray was added to their current supportive treatment. All four patients showed rapid improvement of their clinical symptoms with a shorter than average time to negativization on repeat nasopharyngeal swab via RT-PCR. No safety issues were encountered during the course of treatment. Given its years of excellent safety profile with remarkable clinical results as shown in this case series, we conclude that CPM nasal spray may be a potential adjunct treatment option in patients with mild to moderate COVID-19 symptoms.","PeriodicalId":90141,"journal":{"name":"Clinical & experimental pharmacology","volume":"11 1","pages":"1-3"},"PeriodicalIF":0.0,"publicationDate":"2021-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48150943","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predicting the Severity of Disease Progression in COVID-19 at the Individual and Population Level: A Mathematical Model.","authors":"Narendra Chirmule,&nbsp;Ravindra Khare,&nbsp;Pradip Nair,&nbsp;Bela Desai,&nbsp;Vivek Nerurkar,&nbsp;Amitabh Gaur","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The impact of COVID-19 disease on health and economy has been global, and the magnitude of devastation is unparalleled in modern history. Any potential course of action to manage this complex disease requires the systematic and efficient analysis of data that can delineate the underlying pathogenesis. We have developed a mathematical model of disease progression to predict the clinical outcome, utilizing a set of causal factors known to contribute to COVID-19 pathology such as age, comorbidities, and certain viral and immunological parameters. Viral load and selected indicators of a dysfunctional immune response, such as cytokines IL-6 and IFNα which contribute to the cytokine storm and fever, parameters of inflammation D-Dimer and Ferritin, aberrations in lymphocyte number, lymphopenia, and neutralizing antibodies were included for the analysis. The model provides a framework to unravel the multi-factorial complexities of the immune response manifested in SARS-CoV-2 infected individuals. Further, this model can be valuable to predict clinical outcome at an individual level, and to develop strategies for allocating appropriate resources to manage severe cases at a population level.</p>","PeriodicalId":90141,"journal":{"name":"Clinical & experimental pharmacology","volume":"11 5","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8343949/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39293251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Overview and Innovation of Ovarian Cancer in Developed and Developing Country","authors":"S. Surapaneni, N. Vb, Pooja Jain Vn","doi":"10.35248/2161-1459.21.S9.007","DOIUrl":"https://doi.org/10.35248/2161-1459.21.S9.007","url":null,"abstract":"Ovarian cancer is referred as impairment due to asymptomatic existence. It is task for oncologist because of its serious health conditions. Most cancer is a crew of illness which is caused by means of multiplication or increase of cells, i.e. in out of control and spread to different a part of the body. They additionally recognized as â€oeSilent killer†also refer as ‘Ovarian carcinoma’. It is a deadly disease mostly involved in women over 40 years of age or upto 55-64. It is the 6th common tumor. In 20’s and 30’s of age it is exceedingly rare to occur. Some studies recognize that, now a day’s pregnant ladies also diagnosed with ovarian cancer. Adnexal tumor is identified in most of the cases. They show that malignancy is rising in the course of pregnancy. In every year, more than 200,000 new instances are identified. Ovarian cancer often goes undetected until it has spread within the pelvis and stomach. At that last stage, it is more difficult to treat and can be fatal. Because ovarian cancer has no symptoms in the early stage’s treatment will be delayed. Its treatment will depend on stages. Surgery and chemotherapy are generally used to treat ovarian cancer. Chemotherapy was done by administration of 6 cycles of intravenous with Carboplatin and Paclitaxel along with radiation therapy and also some other drugs which used in the treatment are Metformin, Bevacizumab. Novel targeted therapies are the advanced treatment for screening and understanding of ovarian cancer. In targeted therapies mainly Nanotechnology based drugs are developed for reduction of toxicity and side effects. The article aims to analyse the recent studies and review on general information such as epidemiology, symptoms, risk factors, early detection, imaging or screening, diagnosis, staging, prevention, management and recent studies. The paper also aims to provide insight into the quality-of-life concerns of ovarian cancer patients such as how the treatment will affect the patient, how they survive, support services, society and also discuss about how the current situation COVID-19 will affect the patients.","PeriodicalId":90141,"journal":{"name":"Clinical & experimental pharmacology","volume":"131 1","pages":"1-7"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69986379","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Note on Diagnosis of Human Plasma Proteome","authors":"Abea Voku","doi":"10.35248/2161-1459.21.S8.004","DOIUrl":"https://doi.org/10.35248/2161-1459.21.S8.004","url":null,"abstract":"The human plasma proteome holds the guarantee of infection analysis and restorative observing that has given those significant difficulties in proteomics and related disciplines to be tended. Plasma isn't just the essential clinical example yet additionally addresses the biggest and most profound form of the human proteome present in any example: notwithstanding the traditional \"plasma proteins” it contains all tissue proteins (as spillage markers) in addition to extremely various immunoglobulin successions, and it has an exceptional powerful reach in that in excess of 10 significant degrees in fixation separate egg whites and the most extraordinary proteins currently estimated clinically [1-4].","PeriodicalId":90141,"journal":{"name":"Clinical & experimental pharmacology","volume":"1 1","pages":"1-2"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69986704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quantitative Systems Pharmacology Uses in Drug Development","authors":"Abea Voku","doi":"10.35248/2161-1459.21.11.285","DOIUrl":"https://doi.org/10.35248/2161-1459.21.11.285","url":null,"abstract":"QSP is a computational model that examines the interface between discrete experimental data (studies of the drug/ compound) and the system. The system can be any biological process related to the disease such as the physiological consequences of a disease, a specific disease pathway (signal transduction or up/down regulation of a pathway, increased heart rate), or any of the omics (genomics, proteomics, metabolomics).","PeriodicalId":90141,"journal":{"name":"Clinical & experimental pharmacology","volume":"11 1","pages":"1-2"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69985043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Brief Note on Hyperglycemia-High Blood Sugar","authors":"Abea Voku","doi":"10.35248/2161-1459.21.11.287","DOIUrl":"https://doi.org/10.35248/2161-1459.21.11.287","url":null,"abstract":"","PeriodicalId":90141,"journal":{"name":"Clinical & experimental pharmacology","volume":"11 1","pages":"1-1"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69985957","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Note on Uses of Test of Pharmacogeny","authors":"N. Sanista, Ez","doi":"10.35248/2161-1459.21.11.E163","DOIUrl":"https://doi.org/10.35248/2161-1459.21.11.E163","url":null,"abstract":"","PeriodicalId":90141,"journal":{"name":"Clinical & experimental pharmacology","volume":"11 1","pages":"1-1"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69986297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Note on Technology of Bioinformatics Used for Proteomics","authors":"N. Sanista, Ez","doi":"10.35248/2161-1459.21.S8.005","DOIUrl":"https://doi.org/10.35248/2161-1459.21.S8.005","url":null,"abstract":"","PeriodicalId":90141,"journal":{"name":"Clinical & experimental pharmacology","volume":"1 1","pages":"1-2"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69986322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Study on Neural, Astrocyte and Oligodendrocyte Markers","authors":"Saangi Catherine","doi":"10.35248/2161-1459.21.11.288","DOIUrl":"https://doi.org/10.35248/2161-1459.21.11.288","url":null,"abstract":"","PeriodicalId":90141,"journal":{"name":"Clinical & experimental pharmacology","volume":"11 1","pages":"1-2"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69985999","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}